By now, this news is relatively old: AliveCor’s innovative ECG Case for the iPhone created by Dr. Dave Alpert, MD received FDA approval. But for something this innovative, it’s never too late to give your take. Like my good friend and fellow physician-blogger John Mandrola, MD, I was fortunate to have served as a beta tester of the device.John gives his take here and mentions some great anecdotes of how he has used the device clinically.
While I haven’t been using the device as long as John, I was impressed at the device’s ease of use, intuitive software design, and handsome appearance. While the case itself is not as sturdy as some more robust protective cases, it appeared to protect my phone sufficiently after it slipped from my pocket on more than one occasion as I changed into scrubs. Set-up was a snap and required only the case to be shipped to my house andan app downloaded from Apple’s App store. After entering a few simple pre-requisite bits of information (like the web-based server name the device connected to for demo ECG-uploading purposes), the device was ready to go.
The device uses a simple 3.0V CR2016 batteryto operate. It does NOT require the Bluetooth option on the iPhone to be enabled to function properly and therefore does not interfere with handsfree operation of the phone while driving a Bluetooth-enabled car. The software did not appear to interfere with any other applications on my phone.
Signal quality was pretty good but is subjected to small amounts of baseline noise and driftif the device is not held still and person’s hands were not warm and moist. Adding a bit of alcohol to the finger tips greatly improved the clarity of the signal when needed.The device can be used in several ways: with hands grasping the electrodes on the back of the device or by placing the device directly on the skin of the chest. I found the device worked reliably when the hands were used to record the EKG but placement of the device on the chest occassionally failed to record the ECG signal because of less-reliable contact if the skin was not prepped first. Skin skin prep with alcohol seemed to solve this short-coming.
Lead I of the standard EKG was recorded with the left and right hand holding the device with the left and right hand fingertips touching the electrodes on the back of the case. It was important to hold the device with the iPhone’s round button to the right to assure the device did not record an inverted lead I.
While the images recorded by the device are not easily incorporated into an EMR (at least for now), the device can upload the tracings to AliveCor’s server for web-browsing, create Adobe pdf images for viewing, or send those pdf imagesto any email address worldwide in seconds. It also can detect local wireless Apple printers automatically to print the tracings(though I did not test this feature). Finally, tracings were stored with date and time stamps for easy recall on an internal database that held plenty of tracings easily on my iPhone 4S. I found its greatest weakness was requiring that patient name and demographic information beentered manually. Trust me: dialing back to a 1929 birthdate using the canned iPhone date function was too time-consuming. Hopefully direct data entry of dates will be allowed in future software upgrades.
Without exception, every physician I showed this device recognized this device as a compliment to the doctor’s stethoscope. It was a uniform hit as they gazed in amazement at the device’s ability to record their real-time ECG. I found thisdevice was capable of instantly differentiating the irregular rhythm of atrial fibrillation from the irregular rhythm caused by premature atrial or premature ventricular beats or even atrial flutter with variable AV conduction. Some care was required to get noise-free tracings or to obtain the appropriate EKG vector on the chest with which to identify lower-amplitude atrial arrhythmias. But most limb leads can be replicated by the device (hold the R electrode with the hand and apply the left electrode to the knee to see lead II, for instance), or angle the leads in different directions on the patient’s chest to obtain a new QRS vector. (Obviously, the angle the electrodes were placed on the chest to acquire a particular limb leadrequires some rudimentary knowledge of ECG basics.)
Perhaps the most interesting aspect of this device is what happened when it is placed in the hands of patients and friends unfamiliar with ECG tracings. Their first reaction as they sit transfixed at their own ECG tracing dancing across the screen is “Cool! …. But what does it MEAN?” Then comes “Am I okay?” And then of course when tracings are compared between friends: “Why is my heart rate so much faster/slower than his/hers?” Or you might hear: “Man, I’m out of shape!” And if the device occasionally had difficulty calculating the heart rate from a noisy tracing, three little dashes would appear instead, leading the person to ask, “Does this mean I’m dead?” Any one of these reactions could came from generally healthy people who have never had a major medical problem.What was more interesting to me was the nuanced reaction I noticed from patients who had had a complex medical history before but were seeing this device outside a medical facility for the first time. When they encountered this device in a social setting, it was commonthat these patientsrefusedto have their tracing performed “for fun” for fear they might be sent packing to the nearest medical establishment. It became immediately clear that discretion should be exercised if the device is to be passedabout at cocktail parties. (Yes, doctor, not everyone wants to see your cool gizmo.)
Hence, it appears that deploying this device on the general public has some challenges ahead, but I suspect it will come: gradually at first, then more generally. It is clear that this really does take an understanding of ECGs to use effectively, so doctors (or techs) familiar with ECGs will have to be involved. Liability and responsibility for reading remains a thorny issue one the device is released to the public. I suspect these are relatively easy issues to resolve for AliveCor going forward.Still, for doctors and medically-savvy patients, this device is a game-changer. The number of ECG tracings obtained in clinics will probably diminish one day as this deviceenjoys a wider distribution amongst physicians since it doesn’trequire a special technician or equipment to obtain much of the information doctors need to manage their arrhythmia patients.
But caution with thissingle lead ECG device should be maintained, too. Because multiple ECGleads are notcollected simultaneously, the device could miss the subtle findings of a heart attack in locations remote from the there the single tracing is collected by the device. Still,for routine rhythm analysis, this device has huge potential for time-savings, practical rhythm interpretation, and maybe even the potential to provide for considerable technical health carecost savings.-Wes
PS: I have no commercial interest in AliveCor (darn it).